help button home button Endocrine Society Endocrine Reviews
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

First published online on November 29, 2007
Endocrine Reviews, doi:10.1210/er.2007-0023
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow RPHR Note
Right arrow All Versions of this Article:
29/3/351    most recent
Final Manuscript
Author Manuscript
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Poitout, V.
Right arrow Articles by Robertson, R. P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Poitout, V.
Right arrow Articles by Robertson, R. P.
Endocrine Reviews 29 (3): 351-366
Copyright © 2008 by The Endocrine Society

Glucolipotoxicity: Fuel Excess and β-Cell Dysfunction

Vincent Poitout and R. Paul Robertson

Montreal Diabetes Research Center (V.P.), Centre de Recherche du Centre Hospitalier de l'Université de Montréal, and Departments of Medicine, Nutrition, and Biochemistry, Université de Montréal, Montréal, Québec, Canada H1W 4A4; and Pacific Northwest Diabetes Research Institute, Seattle, Washington 98122; and Departments of Medicine and Pharmacology (R.P.R.), University of Washington, Seattle, Washington 98195

Correspondence: Address all correspondence and requests for reprints to: Vincent Poitout, D.V.M., Ph.D., Montreal Diabetes Research Center, CR-CHUM, Technopole Angus, 2901 Rachel Est, Montreal, Quebec, Canada H1W 4A4. E-mail: vincent.poitout{at}umontreal.ca

Glucotoxicity, lipotoxicity, and glucolipotoxicity are secondary phenomena that are proposed to play a role in all forms of type 2 diabetes. The underlying concept is that once the primary pathogenesis of diabetes is established, probably involving both genetic and environmental forces, hyperglycemia and very commonly hyperlipidemia ensue and thereafter exert additional damaging or toxic effects on the β-cell. In addition to their contribution to the deterioration of β-cell function after the onset of the disease, elevations of plasma fatty acid levels that often accompany insulin resistance may, as glucose levels begin to rise outside of the normal range, also play a pathogenic role in the early stages of the disease. Because hyperglycemia is a prerequisite for lipotoxicity to occur, the term glucolipotoxicity, rather than lipotoxicity, is more appropriate to describe deleterious effects of lipids on β-cell function. In vitro and in vivo evidence supporting the concept of glucotoxicity is presented first, as well as a description of the underlying mechanisms with an emphasis on the role of oxidative stress. Second, we discuss the functional manifestations of glucolipotoxicity on insulin secretion, insulin gene expression, and β-cell death, and the role of glucose in the mechanisms of glucolipotoxicity. Finally, we attempt to define the role of these phenomena in the natural history of β-cell compensation, decompensation, and failure during the course of type 2 diabetes.




This article has been cited by other articles:


Home page
Endocr. Rev.Home page
X. Huang, D. J. Moore, R. J. Ketchum, C. S. Nunemaker, B. Kovatchev, A. L. McCall, and K. L. Brayman
Resolving the Conundrum of Islet Transplantation by Linking Metabolic Dysregulation, Inflammation, and Immune Regulation
Endocr. Rev., August 1, 2008; 29(5): 603 - 630.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
C. P. Tan, Y. Feng, Y.-P. Zhou, G. J. Eiermann, A. Petrov, C. Zhou, S. Lin, G. Salituro, P. Meinke, R. Mosley, et al.
Selective Small-Molecule Agonists of G Protein-Coupled Receptor 40 Promote Glucose-Dependent Insulin Secretion and Reduce Blood Glucose in Mice
Diabetes, August 1, 2008; 57(8): 2211 - 2219.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society